Mitochondrial targeting by a new class of gadolinium agents

新型钆制剂的线粒体靶向

• 批准号: DP190103461
• 负责人: Prof Louis Rendina
• 金额: $ 29.49万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-10-14 至 2024-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP190103461
• 关键词: Mitochondrial; targeting; new; class; gadolinium

This research project will lead to the development of new molecular agents containing the element gadolinium which can selectively accumulate within cell mitochondria, with a long-term application in cutting-edge therapies involving X-rays or neutrons. The lanthanoid element gadolinium offers many unique opportunities for medicinal chemistry and this project will generate new knowledge in bioinorganic chemistry and synchrotron science. The expected outcomes of this research will address many of the unresolved questions regarding mitochondrially-targeted gadolinium complexes, the first such agents specifically designed for potential long-term application in binary therapies and imaging.

这项研究项目将导致含有Gd元素的新分子试剂的开发，这种元素可以选择性地积累在细胞线粒体中，并在涉及X射线或中子的尖端治疗中长期应用。稀土元素Gd为药物化学提供了许多独特的机会，该项目将产生生物无机化学和同步辐射科学方面的新知识。这项研究的预期结果将解决许多关于线粒体靶向Gd络合物的悬而未决的问题，这是第一批专门为潜在的长期应用于二元疗法和成像而设计的此类试剂。